2. Signaling Pathways
  3. Metabolic Enzyme/Protease
    Vitamin D Related/Nuclear Receptor
  4. RAR/RXR

RAR/RXR

Retinoic acid receptors; Retinoid X receptors

RAR/RXR

Related Products

PDF 1.08 MB

The nuclear retinoic acid receptors (RARs) are transcriptional transregulators, which control the expression of specific gene subsets subsequently to ligand binding and to strictly controlled phosphorylation processes. RARs consist of three subtypes, α (NR1B1), β (NR1B2) and γ (NR1B3), encoded by separate genes. RARs function as ligand-dependent transcriptional regulators, heterodimerized with retinoid X receptors (RXRs), which also consist of three types, α NR2B1, β (NR2B2) and γ (NR2B3). RARs play critical roles in a variety of biological processes, including development, reproduction, immunity, organogenesis and homeostasis, as assessed by vitamin A-deficiency (VAD), pharmacological and genetic studies conducted in the mouse.

Retinoid X receptor (RXR) belongs to a family of ligand-activated transcription factors that regulate many aspects of metazoan life. A class of nuclear receptors requires RXR as heterodimerization partner for their function.

RAR/RXR Isoform Specific Products:

RAR/RXR Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-10475G
    AM580 (GMP)
    		Agonist
    AM580 (CD336) (GMP) is AM580 (HY-10475) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AM580 is a selective RARα agonist.
    AM580 (GMP)
  • HY-141793
    ATRA-biotin
    		Agonist
    ATRA-biotin (Biotin-ATRA-conjugate) is a biotin-conjugated ATRA. ATRA-biotin can be used to track ATRA in cells or a given tissue.
    ATRA-biotin
  • HY-N2992
    16α-Hydroxytrametenolic acid
    		Activator ≥98.0%
    16α-Hydroxytrametenolic acid, a natural triterpene, is a potential retinoid X receptor (RXR) selective agonist.
    16α-Hydroxytrametenolic acid
  • HY-14802D
    (-)-Talarozole
    		Inhibitor 98.12%
    (-)-Talarozole is a potent inhibitor of retinoic acid metabolism extracted from patent WO 1997049704 A1.
    (-)-Talarozole
  • HY-106735
    Arotinoid
    		Agonist 99.55%
    Arotinoid (RO 13-6298) is a retinoid, and acts as an orally active and highly potent agonist of retinoic acid receptors (RARs) with antipsoriatic effects. Arotinoid has antipapiltoma activity with an ED50 of 0.05 mg/kg. Arotinoid can be used for the research of skin carcinomas.
    Arotinoid
  • HY-14171S
    Bexarotene-d4
    		Agonist 99.11%
    Bexarotene-d4 is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma[1][2][3][4][5].
    Bexarotene-d<sub>4</sub>
  • HY-15388R
    Tazarotene (Standard)
    		Agonist
    Tazarotene (Standard) is the analytical standard of Tazarotene. This product is intended for research and analytical applications. Tazarotene (AGN 190168) is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris. Tazarotene is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Tazarotene (Standard)
  • HY-D1190
    DC271
    		Agonist
    DC271 is a RAR agonist that can be considered a retinoid, eliciting cellular responses consistent with the endogenous retinoid ATRA and the synthetic retinoid EC23. DC271 binds to retinoid protein machinery, including CRABPII, to translocate the endogenous retinoid ATRA into the nucleus.
    DC271
  • HY-121435
    K-8012
    		Antagonist 98.24%
    K-8012, a sulindac (HY-B0008) analog, is a potent antagonist of RXRa. The IC50 value for K-8012 to inhibit 9-cis-RA-induced Gal4-RXRa-LBD trans-activation were about 9.2 μM. K-8012 exerts improved anticancer activity over sulindac in a RXRa-dependent manner. K-8012 exhibits activity in inhibiting the tRXRa-mediated PI3K/AKT signaling pathway. K-8012 induces apoptosis and inhibits AKT activation by preventing tRXRa from binding to p85a.
    K-8012
  • HY-133739
    NBD-125
    		Inhibitor
    NBD-125 (B-12), a berberine analogue, is an RXRα activator, with an IC50 of 31.10 μM in KM12C cell.
    NBD-125
  • HY-U00449G
    AGN 193109 (GMP)
    		Antagonist
    AGN 193109 (GMP) is AGN 193109 (HY-U00449) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AGN 193109 is a specific and highly effective retinoic acid receptor (RAR) antagonist. AGN 193109 (GMP) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. AGN 193109 is the antidote for retinoic acidosis, that ameliorates the skin and mucosal toxicity.
    AGN 193109 (GMP)
  • HY-149086
    BPA-B9
    		Antagonist
    BPA-B9 is a RXRα ligand and antagonist targeting the pRXRα-PLK1 interaction. BPA-B9 has excellent RXRα-binding affinity (KD=39.29 ± 1.12 nM). BPA-B9 inhibits the proliferation of cancer cells by inducing mitotic arrest and cell apoptosis.
    BPA-B9
  • HY-14802C
    (+)-Talarozole
    		Inhibitor 99.28%
    (+)-Talarozole is a potent inhibitor of retinoic acid metabolism extracted from patent WO 1997049704 A1.
    (+)-Talarozole
  • HY-15388S
    Tazarotene-d8
    		Agonist
    Tazarotene-d8 is the deuterium labeled Tazarotene. Tazarotene (AGN 190168) is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris[1][2].
    Tazarotene-d<sub>8</sub>
  • HY-U00449S
    AGN 193109-d7
    		Antagonist
    AGN 193109-d7 is the deuterium labeled AGN 193109. AGN 193109 is a retinoid analog, and acts as a specific and highly effective antagonist of retinoic acid receptors (RARs), with Kds of 2 nM, 2 nM, and 3 nM for RARα, RARβ, and RARγ, respectively.
    AGN 193109-d<sub>7</sub>
  • HY-169863
    DC360
    		Agonist
    DC360 is a synthetic retinoid analogue of all-trans retinoic acid (ATRA) which induces RARβ expression. DC360 can be utilized in characterization of retinoid signalling pathways.
    DC360
  • HY-106963
    ALRT1550
    		Agonist
    ALRT1550 (LGD1550) is a selective retinoic acid receptor (RAR) agonist that binds RARs with exceptional potency, with Kd values of approximately 1-4 nM. ALRT1550 exhibits anti-proliferative activity, with an IC50 value of 0.22 nM in UMSCC-22B squamous carcinoma cells. In a mouse tumor xenograft model, ALRT1550 inhibited tumor growth in a dose-dependent manner, achieving a maximum inhibition rate of 89%. ALRT1550 is applicable for research in the field of cancer.
    ALRT1550
  • HY-112077A
    Viaminate
    		Activator
    Viaminate is a derivative of Retinoic acid, which is used for the treatment of severe acne and other keratinization disorders.
    Viaminate
  • HY-106019A
    Liarozole hydrochloride
    		Inhibitor
    Liarozole hydrochloride is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole hydrochloride inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC50=7 μM), resulting in increased tissue levels of retinoic acid. Liarozole hydrochloride shows antitumoral properties.
    Liarozole hydrochloride
  • HY-N13361
    Elodeoidileon A
    		Agonist
    Elodeoidileon A is an agonist for RXRα, that interacts with RXRα-LBD protein with a dissociation constant Kd of 5.85 μM. Elodeoidileon A promotes the expression of ATP-binding cassette transporter A1 (ABCA1). Elodeoidileon A reveals the potential in Alzheimer's disease research.
    Elodeoidileon A
Cat. No. Product Name / Synonyms Application Reactivity
RAR/RXR Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.